Skip to content
Taxonomy
Gene Replacement Therapy in CMT4 Subtypes
The Charcot-Marie-Tooth Association (CMTA) has announced a $240K investment in Read More
Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy
In a groundbreaking three-year joint project between the Charcot-Marie-Tooth Association Read More
Repurposing Drugs for CMT1A: An Encouraging Approach
Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form Read More
DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Read More
Summer 2024 CMTA Report: A Season of Renewal and Progress
VIEW IN BROWSER In this issue of The CMTA Report, Read More
CMT-SORD: Share Your Story
CMT-SORD: What is Your Story? For many with CMT, the Read More
Chris Oviatt – Golfer with CMT
Chris Oviatt is a golfer from Oregon who was diagnosed Read More
CMTA Announces New Center of Excellence in Thailand
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Read More
CMTA Appoints David Skarinsky to its Therapy Expert Board
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
The Charcot-Marie-Tooth Association (CMTA) is excited to share that our Read More
